Prior to joining E-Scape, Ms. Smith was president and chief executive officer of
Nuredis, a biotechnology company focused on neurodegenerative diseases caused
by long nucleotide repeats such as Huntington's disease. She previously served
as president and CEO of Raptor Pharmaceuticals, which developed and
commercialized therapies for the orphan disease nephropathic cystinosis and
chronic pulmonary infections in cystic fibrosis before its acquisition by Horizon
Pharmaceuticals. Ms. Smith also served as chief commercial officer of Enobia
Pharmaceuticals until it was acquired by Alexion in 2012.
Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme
and Bristol-Myers Squibb. Ms. Smith serves as a director on the boards of Exelixis, Inc.
(EXEL) and Audentes Therapeutics (BOLD). Ms. Smith obtained her Bachelor of
Science in biology from Cornell University.
